Population‐level study of older adults identifies risk factors for cognitive decline

Population‐level study of older adults identifies risk factors for cognitive decline

In older adults with abdominal obesity (excess belly fat), sustained elevations of blood sugar were linked to a higher likelihood of experiencing cognitive decline. In older adults without abdominal obesity, the hormone adiponectin appeared to be a likely risk factor for cognitive decline. The study, which is published in the Journal of the American Geriatrics Society , included 478 individuals aged 65 years or older who were examined annually for 10 years, with funding from the National Institute on Aging. The findings--which were only observed among those younger than 87 to 88 years old--may eventually point to different strategies for preventing cognitive decline in different groups of older adults. This was population-level research, and the next steps should be in-depth clinical and laboratory studies to fully understand the biological mechanisms underlying the associations that we observed." Mary Ganguli, MD, MPH, lead author, University of Pittsburgh School of Medicine Source: Wiley Journal reference: Ganguli, M., et al. (2020) Aging, Diabetes, Obesity, and Cognitive Decline: A Population‐Based Study. Journal of the American Geriatrics Society. doi.org/10.1111/jgs.16321 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More